NCT03589222 2026-02-27
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
PETHEMA Foundation
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT07437170 2026-02-27
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
The Children's Hospital of Zhejiang University School of Medicine
Phase 2 Active not recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT04898894 2026-01-26
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 1 Active not recruiting
NCT04640779 2026-01-06
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Active not recruiting
NCT02091245 2025-12-02
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03147885 2025-09-29
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Active not recruiting
NCT07094464 2025-07-30
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT04717700 2025-03-18
SABLe
Odense University Hospital
Phase 2 Active not recruiting
NCT04756401 2024-09-26
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Active not recruiting